How Type 2 Inflammation Influences Treatment Choices

Panelists discuss how identifying type 2 inflammation in patients influences treatment decisions by steering clinicians toward targeted therapies, such as biologics or other immunomodulators, that specifically address the underlying inflammatory mechanisms rather than relying solely on symptomatic treatments.

EP: 1.Navigating the Challenges of Respiratory Diseases

EP: 2.The Impact of Atopic Dermatitis and Prurigo Nodularis

EP: 3.Linking Type 2 Inflammation to Asthma and COPD

EP: 4.Impact of Exacerbations in Type 2 Inflammatory Respiratory Diseases

EP: 5.Type 2 Inflammation: The Link Between AD and PN

EP: 6.Personalizing Treatment Selection

EP: 7.Navigating Treatment Challenges in Chronic Skin Conditions

EP: 8.Role of Biologics in Dermatological Care

EP: 9.Biomarkers as Tools in Management of Type 2 Inflammation

EP: 10.Strategies to Manage Type 2 Inflammation in Respiratory Diseases

EP: 11.Addressing Unmet Needs and Emerging Agents

EP: 12.Future Directions for Type 2 Inflammation Management

EP: 13.Type 2 Inflammatory Diseases and Impact on Quality of Life

EP: 14.Type 2 Inflammation Biomarkers

Now Viewing

EP: 15.How Type 2 Inflammation Influences Treatment Choices

• In your experience, how does knowing a patient has type 2 inflammation influence the choice in treatment?

Related Videos

Related Content

Advertisement

October 1st 2024

From CARs to Trispecifics, More Choices to Come in Multiple Myeloma

Mary Caffrey

Ajai Chari, MD, covered both recent FDA approvals and pipeline products, such as non-BCMA chimeric antigen receptor (CAR) T-cell therapies and trispecifics, during a symposium on Immunotherapy at the International Myeloma Society 21st Annual Meeting & Exposition.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

September 30th 2024

Amivantamab Presents an Exciting Treatment Opportunity in NSCLC

Maggie L. Shaw

In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals from the FDA for use in non–small cell lung cancer (NSCLC).

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

September 30th 2024

Ovarian Cancer Awareness Month: Prioritizing Early Detection, Bridging Equity Gaps

Brooke McCormick

September marked Ovarian Cancer Awareness Month, highlighting the importance of early detection and the need for equitable treatment access.

September 29th 2024

Efficacy of Finerenone Around Recent Worsening Heart Failure

Laura Joszt, MA

Finerenone is at least as effective in patients who are in the hospital or were recently hospitalized for heart failure as those with stable condition, said Akshay Desai, MD, of Brigham & Women’s Hospital.

Related Content

Advertisement

October 1st 2024

From CARs to Trispecifics, More Choices to Come in Multiple Myeloma

Mary Caffrey

Ajai Chari, MD, covered both recent FDA approvals and pipeline products, such as non-BCMA chimeric antigen receptor (CAR) T-cell therapies and trispecifics, during a symposium on Immunotherapy at the International Myeloma Society 21st Annual Meeting & Exposition.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

September 30th 2024

Amivantamab Presents an Exciting Treatment Opportunity in NSCLC

Maggie L. Shaw

In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals from the FDA for use in non–small cell lung cancer (NSCLC).

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

September 30th 2024

Ovarian Cancer Awareness Month: Prioritizing Early Detection, Bridging Equity Gaps

Brooke McCormick

September marked Ovarian Cancer Awareness Month, highlighting the importance of early detection and the need for equitable treatment access.

September 29th 2024

Efficacy of Finerenone Around Recent Worsening Heart Failure

Laura Joszt, MA

Finerenone is at least as effective in patients who are in the hospital or were recently hospitalized for heart failure as those with stable condition, said Akshay Desai, MD, of Brigham & Women’s Hospital.